Buchumschlag

Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Silvio Danese, Rupert W. Leong, Bruce E. Sands, Tony Ma, Colleen Marano, Laurent Peyrin‐Biroulet
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Systematic Review: Ultrasound Goes Echo—Decarbonising Inflammatory Bowel Disease Care Through Intestinal Ultrasound
von: Sara Massironi, et al.
Veröffentlicht: (2025)

Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT‐UC Consortium
von: Parambir S. Dulai, et al.
Veröffentlicht: (2024)

Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease
von: Léa Sequier, et al.
Veröffentlicht: (2024)

Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis—Where We Are Now in Real Life. Authors' Reply
von: María Chaparro, et al.
Veröffentlicht: (2024)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter
von: Anish J. Kuriakose Kuzhiyanjal, et al.
Veröffentlicht: (2025)

Long‐Term Outcomes of an Infliximab‐First Versus Vedolizumab‐First Treatment Strategy in Biologic‐Naïve Patients With Ulcerative Colitis
von: Austin Haynesworth, et al.
Veröffentlicht: (2024)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter: Authors' Reply
von: Aakash Desai, et al.
Veröffentlicht: (2025)

Clinical Trial: Evaluating a Single 1600 mg Tablet Regimen of 5‐Aminosalicylate for Ulcerative Colitis—The EASI Trial
von: Rie Louise Møller Nordestgaard, et al.
Veröffentlicht: (2025)

Editorial: Striving for Equitable Care in Ulcerative Colitis
von: Edward L. Barnes
Veröffentlicht: (2025)

Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis
von: Richard Pollok
Veröffentlicht: (2025)

Clinical Trial: Long Versus Short Tapering of Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis—A Randomised Controlled Trial
von: Ankit Kumar, et al.
Veröffentlicht: (2026)

Meta‐Analysis: Exclusive Enteral Nutrition in Adults With Ulcerative Colitis
von: Matthew K. W. Chu, et al.
Veröffentlicht: (2025)

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
von: Antoine Meyer, et al.
Veröffentlicht: (2025)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
von: Zhidong Zhou, et al.
Veröffentlicht: (2025)

Obesity Is Associated With Worsened Outcomes in Patients With Ulcerative Colitis on Advanced Therapies: A Propensity Matched Cohort Study From the U.S.
von: Aakash Desai, et al.
Veröffentlicht: (2025)

Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis—Hope Beyond Monotherapy
von: Ahmed B. Bayoumy, et al.
Veröffentlicht: (2025)

Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis
von: Arshdeep Singh, et al.
Veröffentlicht: (2025)

Letter: Steroid Tapering in Ulcerative Colitis: The Importance of Disease Severity and Maintenance Therapy
von: Rónán O'Connor, et al.
Veröffentlicht: (2026)

Editorial: Evolving Trends in Ulcerative Colitis Management—Insights From the Lothian Cohort
von: Shintaro Akiyama
Veröffentlicht: (2025)

Temporal Trends in Medical and Surgical Management of Ulcerative Colitis in England: 2003–2020
von: J. Couch, et al.
Veröffentlicht: (2025)

Editorial: The Appendix—A Dead End for Treating Ulcerative Colitis, After All?
von: Johan D. Söderholm
Veröffentlicht: (2025)

Letter: Exclusive Enteral Nutrition in Ulcerative Colitis—The Path Ahead Needs Careful Consideration
von: Sarah Melton, et al.
Veröffentlicht: (2025)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse
von: Mark A. Ainsworth, et al.
Veröffentlicht: (2025)

Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT ‐ UC Consortium
von: Brian C. Weiner
Veröffentlicht: (2025)

Factors Associated With Abdominal Pain in Patients With Active and Quiescent Ulcerative Colitis: A Multicohort Study
von: Tom van Gils, et al.
Veröffentlicht: (2024)

The Association of Faecal Calprotectin Measurements With Endo‐Histological Remission in Ulcerative Colitis: A Pooled Analysis
von: Laurie‐Rose Dubé, et al.
Veröffentlicht: (2026)

Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply
von: Ankit Kumar, et al.
Veröffentlicht: (2026)

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study
von: Mathilde Osty, et al.
Veröffentlicht: (2025)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse. Authors' Reply
von: Shinichiro Shinzaki, et al.
Veröffentlicht: (2025)

Editorial: Ulcerative Colitis Management in the Biologic Era–Data From the English Healthcare Databases. Authors' Reply
von: J. Couch, et al.
Veröffentlicht: (2025)

Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply
von: Merle Claßen, et al.
Veröffentlicht: (2024)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis
von: Ganesh Bhat, et al.
Veröffentlicht: (2026)

Editorial: Understanding Factors Associated With Abdominal Pain in Ulcerative Colitis—No Surprises But the Usual Suspects Need Greater Attention
von: Weilun Gao, et al.
Veröffentlicht: (2024)

Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study
von: Ronen Stein, et al.
Veröffentlicht: (2025)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis. Authors' Reply
von: Amol N. Patil, et al.
Veröffentlicht: (2026)

Efficacy and Safety of Vedolizumab and Tofacitinib ( VETO ) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti‐ TNF and a Second‐Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial
von: Pardhu Bharath Neelam, et al.
Veröffentlicht: (2025)

Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease
von: Thanaboon Chaemsupaphan, et al.
Veröffentlicht: (2024)

Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series
von: Rahul S. Dalal, et al.
Veröffentlicht: (2025)

Letter : Is Short Tapering of Steroids in Moderate to Severely Active Ulcerative Colitis Really Inferior to a Long Steroid Taper, or Just Underpowered to Reach a Definitive Conclusion?
von: Hariti Saluja, et al.
Veröffentlicht: (2026)

Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease
von: Tsz Hong Yiu, et al.
Veröffentlicht: (2024)